Menu Search
Equities

Camurus AB

CAMX:STO

Camurus AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)615.00
  • Today's Change-16.00 / -2.54%
  • Shares traded129.98k
  • 1 Year change+75.11%
  • Beta0.9754
Data delayed at least 15 minutes, as of Nov 08 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Camurus AB grew revenues 79.52% from 956.34m to 1.72bn while net income improved 676.63% from 55.55m to 431.44m.
Gross margin92.38%
Net profit margin15.76%
Operating margin16.26%
Return on assets9.84%
Return on equity11.57%
Return on investment11.34%
More ▼

Cash flow in SEKView more

In 2023, Camurus AB increased its cash reserves by 110.39%, or 624.30m. The company earned 606.88m from its operations for a Cash Flow Margin of 35.35%. In addition the company generated 28.76m cash from financing while 10.13m was spent on investing.
Cash flow per share4.81
Price/Cash flow per share128.61
Book value per share52.92
Tangible book value per share52.54
More ▼

Balance sheet in SEKView more

Camurus AB has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 1.19bn.
Current ratio8.27
Quick ratio7.91
Total debt/total equity0.0059
Total debt/total capital0.0059
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.